{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:42:57Z","timestamp":1792226577180,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Oral Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cancer treatment-induced bone loss (CTIBL) is the most common adverse event experienced by patients affected by breast cancer (BC) patients, without bone metastases. Bone modifying agents (BMAs) therapy is prescribed for the prevention of CTIBL, but it exposes patients to the risk of MRONJ.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This multicentre hospital-based retrospective study included consecutive non-metastatic BC patients affected by MRONJ related to exposure to low-dose BMAs for CTIBL prevention. Patients\u2019 data were retrospectively collected from the clinical charts of seven recruiting Italian centres.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>MRONJ lesions were found in fifteen females (mean age 67.5 years), mainly in the mandible (73.3%). The mean duration of BMAs therapy at MRONJ presentation was 34.9 months. The more frequent BMAs was denosumab (53.3%).\u00a0Ten patients (66.7%) showed the following local risk factors associated to MRONJ development: periodontal disease (PD) in three cases (20%) and the remaining six (40%) have undergone PD-related tooth extractions. One patient presented an implant presence-triggered MRONJ (6.7%). In five patients (33.3%) no local risk factors were observed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This is the first case series that investigated BC patients under BMAs for CTIBL prevention suffering from MRONJ. These patients seem to have similar probabilities of developing MRONJ as osteo-metabolic ones. Breast\u00a0cancer patients under BMAs for CTIBL prevention need a regular prevention program for MRONJ, since they may develop bone metastases and be treated with higher doses of BMAs, potentially leading to a high-risk of MRONJ.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12903-023-02732-6","type":"journal-article","created":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T15:02:58Z","timestamp":1675522978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series"],"prefix":"10.1186","volume":"23","author":[{"given":"Rodolfo","family":"Mauceri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Coppini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Attanasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bedogni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordana","family":"Bettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amerigo","family":"Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Graziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Marcian\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Nisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Isola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalia Maria","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Oteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Campisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,4]]},"reference":[{"key":"2732_CR1","doi-asserted-by":"publisher","DOI":"10.32388\/594095","volume-title":"Medication related osteonecrosis of the jaw (MRONJ)","author":"A Bedogni","year":"2018","unstructured":"Bedogni A, Campisi G, Fusco V. Medication related osteonecrosis of the jaw (MRONJ). London: Qeios; 2018."},{"key":"2732_CR2","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1111\/odi.13160","volume":"25","author":"M Schiodt","year":"2019","unstructured":"Schiodt M, Otto S, Fedele S, Bedogni A, Nicolatou-Galitis O, Guggenberger R, et al. Workshop of european task force on medication-related osteonecrosis of the jaw\u2014current challenges. Oral Dis. 2019;25:1815\u201321.","journal-title":"Oral Dis"},{"key":"2732_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijerph17165998","volume":"17","author":"G Campisi","year":"2020","unstructured":"Campisi G, Mauceri R, Bertoldo F, Bettini G, Biasotto M, Colella G, et al. Medication-related osteonecrosis of jaws (MRONJ) prevention and diagnosis: Italian consensus update 2020. Int J Environ Res Public Health. 2020;17:1\u201315.","journal-title":"Int J Environ Res Public Health"},{"key":"2732_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00520-018-4501-x","volume":"27","author":"O Nicolatou-Galitis","year":"2019","unstructured":"Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, Epstein JB, et al. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer. 2019;27:383\u201394.","journal-title":"Support Care Cancer"},{"key":"2732_CR5","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1080\/14740338.2016.1177021","volume":"15","author":"V Fusco","year":"2016","unstructured":"Fusco V, Santini D, Armento G, Tonini G, Campisi G. Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology. Expert Opin Drug Saf. 2016;15:925\u201335.","journal-title":"Expert Opin Drug Saf"},{"key":"2732_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2217\/fon.13.211","volume":"10","author":"G Campisi","year":"2014","unstructured":"Campisi G, Fedele S, Fusco V, Pizzo G, Di Fede O, Bedogni A. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncol. 2014;10:257\u201375.","journal-title":"Future Oncol"},{"key":"2732_CR7","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ejim.2013.05.011","volume":"24","author":"O Di Fede","year":"2013","unstructured":"Di Fede O, Fusco V, Matranga D, Solazzo L, Gabriele M, Gaeta GM, et al. Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: a retrospective multi-hospital-based study of 87 Italian cases. Eur J Intern Med. 2013;24:784\u201390.","journal-title":"Eur J Intern Med"},{"key":"2732_CR8","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of oral and maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the Jaws\u20142022 Update. J Oral Maxillofac Surg. 2022;80:920\u201343.","journal-title":"J Oral Maxillofac Surg"},{"key":"2732_CR9","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1007\/s00520-022-06839-4","volume":"30","author":"H Hata","year":"2022","unstructured":"Hata H, Imamachi K, Ueda M, Matsuzaka M, Hiraga H, Osanai T, et al. Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study. Support Care Cancer. 2022;30:4505\u201314.","journal-title":"Support Care Cancer"},{"key":"2732_CR10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mds277","volume":"24","author":"R Coleman","year":"2013","unstructured":"Coleman R, De Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013;24:398\u2013405.","journal-title":"Ann Oncol"},{"key":"2732_CR11","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","volume":"3","author":"GN Hortobagyi","year":"2017","unstructured":"Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, et al. Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. JAMA Oncol. 2017;3:906\u201312.","journal-title":"JAMA Oncol"},{"key":"2732_CR12","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of oral and maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update. J Oral Maxillofac Surg. 2014;72:1938\u201356.","journal-title":"J Oral Maxillofac Surg"},{"key":"2732_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-021-00835-2","volume":"22","author":"A Diana","year":"2021","unstructured":"Diana A, Carlino F, Giunta EF, Franzese E, Guerrera LP, Di Lauro V, et al. Cancer Treatment-Induced Bone loss (CTIBL): state of the art and proper management in breast Cancer patients on endocrine therapy. Curr Treat Options Oncol. 2021;22:1\u201317.","journal-title":"Curr Treat Options Oncol"},{"key":"2732_CR14","unstructured":"World Health Organization. Global Cancer Observatory - GLOBOCAN 2020. https:\/\/gco.iarc.fr\/databases.php. Accessed 2 Sep 2021."},{"key":"2732_CR15","unstructured":"WHO. Breast cancer. 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer. Accessed 28 June\u00a02022."},{"key":"2732_CR16","unstructured":"World Cancer Research Fund International. Breast cancer statistics. World Cancer Research Fund International. https:\/\/www.wcrf.org\/cancer-trends\/breast-cancer-statistics\/. Accessed 31 Aug 2022."},{"key":"2732_CR17","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","volume":"31","author":"R Coleman","year":"2020","unstructured":"Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, et al. Bone health in cancer: ESMO Clinical Practice Guidelines \u2020. Ann Oncol. 2020;31:1650\u201363.","journal-title":"Ann Oncol"},{"key":"2732_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00223-017-0369-x","volume":"102","author":"C Handforth","year":"2018","unstructured":"Handforth C, D\u2019Oronzo S, Coleman R, Brown J. Cancer treatment and bone health. Calcif Tissue Int. 2018;102:251\u201364.","journal-title":"Calcif Tissue Int"},{"key":"2732_CR19","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","volume":"19","author":"P Hadji","year":"2008","unstructured":"Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol. 2008;19:1407\u201316.","journal-title":"Ann Oncol"},{"key":"2732_CR20","first-page":"11","volume":"66","author":"A de Sire","year":"2022","unstructured":"de Sire A, Lippi L, Venetis K, Morganti S, Sajjadi E, Curci C, et al. Efficacy of antiresorptive drugs on bone mineral density in post-menopausal women with early breast cancer receiving adjuvant aromatase inhibitors: a systematic review of randomized controlled trials. Front Oncol. 2022;66:11.","journal-title":"Front Oncol"},{"key":"2732_CR21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","volume":"20","author":"M Gnant","year":"2019","unstructured":"Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:339\u201351.","journal-title":"Lancet Oncol"},{"key":"2732_CR22","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/tbj.12155","volume":"19","author":"AM Brufsky","year":"2013","unstructured":"Brufsky AM, Sereika SM, Mathew A, Tomifumi O, Singh V, Rosenzweig M. Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: a retrospective study. Breast J. 2013;19:504\u201311.","journal-title":"Breast J"},{"key":"2732_CR23","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1007\/s00520-020-05748-8","volume":"29","author":"DA Kizub","year":"2021","unstructured":"Kizub DA, Miao J, Schubert MM, Paterson AHGG, Clemons M, Dees EC, et al. Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). Support Care Cancer. 2021;29:2509\u201317.","journal-title":"Support Care Cancer"},{"key":"2732_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","volume":"21","author":"R Coleman","year":"2020","unstructured":"Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21:60\u201372.","journal-title":"Lancet Oncol"},{"key":"2732_CR25","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.joms.2022.07.143","volume":"80","author":"V Fusco","year":"2022","unstructured":"Fusco V, Mauceri R, Campisi G, Bedogni A. RE: American Association of oral and maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the Jaws\u20142022 update: quantitative risk assessment and controversial issues. J Oral Maxillofac Surg. 2022;80:1871\u20133.","journal-title":"J Oral Maxillofac Surg"},{"key":"2732_CR26","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","volume":"12","author":"E von Elm","year":"2014","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12:1495\u20139.","journal-title":"Int J Surg"},{"key":"2732_CR27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.bjoms.2014.04.009","volume":"52","author":"A Bedogni","year":"2014","unstructured":"Bedogni A, Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, et al. Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease. Br J Oral Maxillofac Surg. 2014;52:603\u20138.","journal-title":"Br J Oral Maxillofac Surg"},{"key":"2732_CR28","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/jbmr.4472","volume":"37","author":"J Everts-Graber","year":"2022","unstructured":"Everts-Graber J, Lehmann D, Burkard JP, Schaller B, Gahl B, H\u00e4uselmann HJ, et al. Risk of osteonecrosis of the Jaw under Denosumab compared to Bisphosphonates in patients with osteoporosis. J Bone Miner Res. 2022;37:340\u20138.","journal-title":"J Bone Miner Res"},{"key":"2732_CR29","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1210\/clinem\/dgab888","volume":"107","author":"AD Anastasilakis","year":"2022","unstructured":"Anastasilakis AD, Pepe J, Napoli N, Palermo A, Magopoulos C, Khan AA, et al. Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS. J Clin Endocrinol Metab. 2022;107:1441\u201360.","journal-title":"J Clin Endocrinol Metab"},{"key":"2732_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jbo.2020.100311","volume":"25","author":"JE Brown","year":"2020","unstructured":"Brown JE, Handforth C, Compston JE, Cross W, Parr N, Selby P, et al. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. J Bone Oncol. 2020;25:66.","journal-title":"J Bone Oncol"},{"key":"2732_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","volume":"379","author":"MR Smith","year":"2012","unstructured":"Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379:39\u201346.","journal-title":"Lancet"},{"key":"2732_CR32","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.jcms.2018.05.003","volume":"46","author":"M Nisi","year":"2018","unstructured":"Nisi M, Karapetsa D, Gennai S, Ramaglia L, Graziani F, Gabriele M. Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up. J Craniomaxillofac Surg. 2018;46:1153\u20138.","journal-title":"J Craniomaxillofac Surg"},{"key":"2732_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40264-017-0582-6","volume":"41","author":"G Oteri","year":"2018","unstructured":"Oteri G, Trifir\u00f2 G, Peditto M, Lo Presti L, Marcian\u00f2 I, Giorgianni F, et al. Treatment of medication-related osteonecrosis of the Jaw and its impact on a patient\u2019s quality of life: a single-center, 10-year experience from Southern Italy. Drug Saf. 2018;41:111\u201323.","journal-title":"Drug Saf"},{"key":"2732_CR34","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/odi.13294","volume":"26","author":"O Nicolatou-Galitis","year":"2020","unstructured":"Nicolatou-Galitis O, Papadopoulou E, Vardas E, Kouri M, Galiti D, Galitis E, et al. Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents. Oral Dis. 2020;26:955\u201366.","journal-title":"Oral Dis"},{"key":"2732_CR35","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.joms.2009.07.086","volume":"68","author":"N Yarom","year":"2010","unstructured":"Yarom N, Fedele S, Lazarovici TS, Elad S. Is exposure of the Jawbone Mandatory for establishing the diagnosis of bisphosphonate-related osteonecrosis of the Jaw? J Oral Maxillofac Surg. 2010;68:705.","journal-title":"J Oral Maxillofac Surg"},{"key":"2732_CR36","first-page":"66","volume":"6","author":"NJ Rao","year":"2017","unstructured":"Rao NJ, Wang JY, Yu RQ, Leung YY, Zheng LW. Role of periapical diseases in medication-related osteonecrosis of the jaws. Biomed Res Int. 2017;6:66.","journal-title":"Biomed Res Int"},{"key":"2732_CR37","first-page":"463","volume":"57","author":"S Otto","year":"2021","unstructured":"Otto S, Aljohani S, Fliefel R, Ecke S, Ristow O, Burian E, et al. Infection as an important factor in medication-related osteonecrosis of the Jaw (MRONJ). Medicine. 2021;57:463.","journal-title":"Medicine"},{"key":"2732_CR38","doi-asserted-by":"publisher","unstructured":"Mauceri R, Panzarella V, Carbone MI, Oteri G, Marcian\u00f3 A et al. fede olga di,. Histological findings of osteonecrosis spotted prior to tooth extractions. Should we consider tooth extraction still the main trigger event? Qeios. 2021. https:\/\/doi.org\/10.32388\/JK459H.2.","DOI":"10.32388\/JK459H.2"},{"key":"2732_CR39","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1007\/s00520-020-05882-3","volume":"29","author":"A Srivastava","year":"2021","unstructured":"Srivastava A, Nogueras Gonzalez GM, Geng Y, Won AM, Cabanillas ME, Naing A, et al. Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer. 2021;29:2305\u201317.","journal-title":"Support Care Cancer"},{"key":"2732_CR40","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.21.02647","volume":"40","author":"A Eisen","year":"2022","unstructured":"Eisen A, Somerfield MR, Accordino MK, Blanchette PS, Clemons MJ, Dhesy-Thind S, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update. J Clin Oncol. 2022;40:787\u2013800.","journal-title":"J Clin Oncol"},{"key":"2732_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/2684924","volume":"2018","author":"O Di Fede","year":"2018","unstructured":"Di Fede O, Panzarella V, Mauceri R, Fusco V, Bedogni A, Lo Muzio L, et al. The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. Biomed Res Int. 2018;2018:1\u201310.","journal-title":"Biomed Res Int"},{"key":"2732_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-06940-8","author":"R Mauceri","year":"2022","unstructured":"Mauceri R, Coniglio R, Abbinante A, Carcieri P, Tomassi D, Panzarella V, et al. The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by italian experts for dental hygienists. Support Care Cancer. 2022. https:\/\/doi.org\/10.1007\/s00520-022-06940-8.","journal-title":"Support Care Cancer"},{"key":"2732_CR43","doi-asserted-by":"publisher","first-page":"482","DOI":"10.21037\/atm.2020.03.55","volume":"8","author":"J-F Huang","year":"2020","unstructured":"Huang J-F, Shen J, Li X, Rengan R, Silvestris N, Wang M, et al. Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. Ann Transl Med. 2020;8:482\u20132.","journal-title":"Ann Transl Med"}],"container-title":["BMC Oral Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-023-02732-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12903-023-02732-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-023-02732-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T15:03:31Z","timestamp":1675523011000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcoralhealth.biomedcentral.com\/articles\/10.1186\/s12903-023-02732-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,4]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2732"],"URL":"https:\/\/doi.org\/10.1186\/s12903-023-02732-6","relation":{},"ISSN":["1472-6831"],"issn-type":[{"value":"1472-6831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,4]]},"assertion":[{"value":"7 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the ethical guidelines of the Declaration of Helsinki (1964) and its later amendments or comparable ethical standards, and it was approved by the central institutional review board (Coordinator Centre approval ID: #4\/2012\u2014\u201cPaolo Giaccone\u201d Policlinico University Hospital in Palermo, Italy). Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All other authors have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}